Baird raised the firm’s price target on Medpace (MEDP) to $354 from $349 and keeps a Neutral rating on the shares. The firm said the sector chop, political headlines galore, and presently weak biotech funding each keep them more guarded than normal. Yet this is exactly the type of company that long-term investors should crave and the firm has a very positive long-term bias on the shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MEDP:
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls
- Medpace price target lowered to $372 from $413 at TD Cowen
- Medpace downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- Medpace reports Q3 EPS $3.01, consensus $2.78
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
